Lumata Health, a leader in personalized support for patients with vision-threatening chronic eye diseases, has secured $23 million in Series B funding to expand its efforts in preventing avoidable vision loss. The latest investment brings the company’s total funding to $36 million since its inception.
Landon Grace, CEO of Lumata Health, is also an associate professor in the Department of Mechanical and Aerospace Engineering (MAE) at North Carolina State University. An accomplished researcher and recipient of the prestigious National Science Foundation (NSF) CAREER Award, Grace has focused his academic career on advanced materials and structural health monitoring using data-driven approaches; work that translated to Lumata’s data-driven approach to identifying and mitigating root causes of vision loss. His work at NC State has fostered a culture of innovation, supporting technology-driven solutions with real-world impact.
The Series B round was co-led by LRVHealth, McKesson Ventures, and Cencora Ventures, with participation from existing investors, including Cortado Ventures. The funding will allow Lumata Health to meet increasing demand and enhance the data-driven technology powering its patient adherence solutions.
“As more specialty medicines reach the market, solutions designed to help patients start and stay on their prescribed treatment regimen are increasingly important,” said Jason Dinger, senior vice president of strategic execution at Cencora Ventures.
Vision loss is a growing public health crisis, with conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration expected to double in prevalence in the coming decades. While effective treatments exist, systemic barriers often delay or prevent timely care. Lumata Health’s platform combines predictive analytics with personalized interventions, enabling the delivery of up to 800 additional vision-saving eye injections annually for every 1,000 participating patients.
“We are thrilled to partner with investors who share our vision for a smarter, more effective approach to preventing blindness from chronic eye diseases,” said Grace. “This investment will allow us to continue scaling our data-driven approach to ensuring access and adherence to vision-saving treatments for the millions of people in the U.S. affected by these conditions.” He added, “The environment of innovation and entrepreneurship at NC State has been essential to getting Lumata to where it is today. The financial support of the Wolfpack Investor Network has been particularly crucial”
Over the past three years, Lumata has established partnerships with leading national and regional eye care networks, demonstrating success in improving treatment adherence, patient satisfaction, and access to care. The involvement of McKesson Ventures and Cencora Ventures underscores Lumata’s role in reducing healthcare costs while delivering value to both providers and patients.
“With millions of Americans at risk of preventable blindness, we’re investing in Lumata Health because it is uniquely positioned to drive meaningful change at scale,” said Ellen Herlacher, partner at LRVHealth. “By combining advanced technology, predictive analytics, and compassionate care, the company is reshaping how chronic eye diseases are managed and ensuring that more patients retain their vision for years to come.”
Lumata Health was founded in 2017 by ophthalmologist Dr. Stephen Fransen and is supported by a team of certified ophthalmic care coaches, data scientists, and healthcare executives. The company partners with physicians, payers, and pharmaceutical manufacturers to improve clinical outcomes while reducing long-term healthcare costs.
NC State’s MAE department continues to be a hub for technological advancement, with faculty like Grace bridging academia and industry to drive meaningful innovations.
For more information, visit lumatahealth.com.